Brand-name pens run $1,000+ per month cash, and insurance rarely covers them for weight loss alone
2022 DOI: 10.1016/j.cmet.2022.07.013 PMID: 35985340 Read on PubMed The Lancet LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial Urva S, Coskun T, Loh MT, et al
Gabe MBN, van der Velden WJC, Smit FX, Gasbjerg LS, Rosenkilde MM
Treating these people with a synthetic GLP-1 supplement, they reasoned, could help restore a healthy insulin response and bring down blood glucose levels
Swirl it gently if needed
Protect from light, moisture, and heat, and avoid repeated freeze-thaw cycles